There have been remarkable changes in gastric cancer treatments in Japan, resulting in superb improvement of prognosis in patients with this disease. In this paper, the last 50 years have been divided into three eras: before 1990; the 1990s; and the era of evidence, which means after 2000. Changes of treatments and prognosis were analyzed by several factors, such as surgery, chemotherapy, informed consent, clinical trials, and others, as improvement of prognosis is not due to one factor but several ones influencing each other.
| TRE ATMENT OF G A S TRIC C AN CER B EFORE 1990

| Earlier stage at diagnosis
In 1960, the screening test for gastric cancer of upper gastrointestinal (UGI) barium contrast swallow was introduced in the Miyagi prefecture and gradually became adopted in many other parts of the country. In 1983, the Japanese Government issued a law requiring each local government to establish a system of screening for several cancers in their territory, including gastric cancer for citizens over the age of 40 years. 1 Although the actual proportion of people undergoing screening was lower than 30%, the public was well-aware of the elevated risk of gastric cancer in Japan.
Because of this increased awareness, people began to seek medical advice very early after the onset of symptoms and were subsequently offered endoscopy. As a result of this increased screening activity, the proportion of early-stage cancers increased year by year (Table 1) . 2 Early detection is likely the most important reason for the improvement of survival for Japanese patients with gastric cancer.
| Efficacy of chemotherapy treatment
Before 1990, the approved chemotherapeutic agents for gastric cancer included 5-FU (1950s), mitomycin-C (MMC) (1960s), Doxorubicin (1970s), cytarabine (1970s), Etoposide (1970s) , and cisplatin (1980s).
The combination of 5-FU, adriamycin, and mitomycin-C (FAM) was initially regarded as the standard regimen. 3 In the late 1980s, combination chemotherapy using etoposide, adriamycin, and cisplatin (EAP) was demonstrated to have a dramatically high response rate. 4 This treatment was soon abandoned, however, due to an unacceptably high incidence of treatment-related death rates. In Japan, a combination of 5-FU or several oral derivatives and MMC became the most commonly used regimen.
| Trends in surgery
With the limited efficacy of non-surgical treatment, surgeons tried to perform more radical surgical procedures in an attempt to improve survival. There was a belief among surgeons that complete resection of all macroscopic tumors, even at distant sites, was the only way to cure gastric cancer. Dr Kajitani reported good results of D2 gastrectomy even for advanced stages. 5 When performing a D2 total gastrectomy, splenectomy and distal pancreatectomy were routinely performed. 6 For some advanced tumors with lymphadenopathy involving the celiac trifurcation, en-bloc resection of the stomach, the distal pancreas and spleen, as well as the vascular pedicles of the stomach (i.e., the celiac artery itself with the common hepatic and splenic arteries), was advocated by the Canadian surgeon, Dr Appleby. 7 This operation, however, showed higher morbidity than a standard total gastrectomy with pancreato-splenectomy and was gradually abandoned in the late 1980s. For large tumors involving the whole stomach like "linitis plastica," an upper abdominal exenteration procedure was advocated by some, which included total gastrectomy, distal pancreatectomy and splenectomy, transverse colectomy with or without left lateral segmentectomy of the liver. 8 As a retrospective comparison of the patients treated at the National Cancer Center Hospital Tokyo demonstrated better long-term survival results with less morbidity for those whose distal pancreas was preserved than those undergoing radical surgical procedures (i.e., pancreato-splenectomy in case of total gastrectomy) the latter was gradually replaced by the former as advocated by Dr Maruyama.
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In some Japanese institutions including the Cancer Institute
Hospital, para-aortic node dissection (PAND) was introduced with results showing a relatively high incidence of metastasis in the para-aortic nodes (PAN) and a 5-year survival rate for those having PAN metastasis of 10%-30%.
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| Telling the truth and informed consent
As recently as the 1980s in Japan, it was common practice for physicians to withhold information about the disease extent and prognosis from their patients to obtain informed consent from the patients' families. Especially in cases of advanced diseases, doctors were often hesitant to reveal the full extent of the disease to the patients themselves. At universities, medical students were often told not to tell the truth to cancer patients for fear that they would become overwhelmed and distraught and potentially even contemplate suicide. Informed consent for clinical trials was also often obtained from patients' family members but not from patients themselves. 13 Compared to the current situation, physician attitudes and practices in this era were, therefore, very paternalistic.
| Limited knowledge of medical statistics among physicians
As 
| Establishment of endoscopic treatment (EMR)
After analyzing the data of thousands of patients with early gastric cancer (EGC), it became evident that some types of EGC rarely have nodal metastases. 15 As a result, methods of endoscopic resection for these early cancers were developed by gastroenterologists. The early experience with endoscopic resection involved polypectomy, which could be applied to cancers with a polypoid morphology. Over time, modifications of the polypectomy technique and the introduction of more sophisticated endoscopic instruments led to the development of endoscopic mucosal resection (EMR), which began to be used for flat lesions of limited size in the 1980s. 
| Influence of large international randomized trials
In 1989, the Dutch D1/D2 study commenced following the Medical Research Council trial which had started a few years earlier. 18, 19 The organizers of the Dutch study made attempts to ensure a high level of quality control in both surgical treatment and accurate pathological evaluation, especially with regards to lymph nodal retrieval and reporting. 20 The results of the Dutch Trial showed that postoperative hospital mortality was as high as 9.8% in the D2 group, which raised significant concerns about the quality of surgery in this trial.
Although efforts had indeed been made to ensure the quality of surgery in this trial, several critical issues were identified: (a) none of participating surgeons except one had ever performed D2 surgery before the study, although an experienced Japanese surgeon performed surgery in the first 30 D2 cases; (b) there was no rigorous vetting process of participating surgeons to ensure the quality of surgery was above a standard level; (c) the treatment of surgical complications was not standardized among institutes, resulting in high mortality rates after anastomotic leakage and pancreatic fistula; (d) the study reported both a high incidence of insufficient nodal dissection (non-compliance) in patients allocated to D2 and a high incidence of over-dissection (contamination) in those allocated to D1; and (e) the data center was not completely independent and allowed frequent access to the survival data for surgical researchers, and (f) alpha spending function concept -an idea to maintain a level of alpha error defined by the study design toward consumption of alpha error by multiple testing during the study -was not applied in this study. Consequently, the survival analysis was carried out several times with little concern about "multiplicity of analysis." 21 Yet, despite these limitations, the Dutch Trial was considered as a major step forward in the field of abdominal oncological surgery trials. 22 The author who participated in the Dutch study as surgical quality controller and instructor subsequently went on to initiate clinical studies in the field of gastric cancer surgery in Japan, beginning with Japan Clinical Oncology Group (JCOG) 9501 and 9502. The former was a prospective randomized controlled trial (RCT) comparing D2
(D3) vs that plus PAND for advanced gastric cancer. 23 The latter was a prospective RCT comparing abdominal and transdiaphragmatic
dissection (AT) vs left thoracoabdominal (LT) approach for gastric
cancer invading the esophagus of 3 cm or less, roughly equivalent to Siewert type 2 and 3 tumors with limited esophageal involvement. 24 The JCOG, the first Japanese co-operative group in oncology, enabled us to perform these studies, providing an independent data center, a data and safety monitoring committee, an independent audit committee, and a framework to lobby for governmental financial support. After these two studies, multiple other phase III studies on gastric cancer surgery were carried out on this group.
| Evaluation of efficacy of nodal dissection in each station
Before the results of these RCTs to demonstrate the benefit of lymph node dissection became available, the efficacy of nodal dissection was estimated using a new process, multiplying the percentage of metastasis by the 5-year survival rate of those having nodal metastasis in each nodal station, using a large number of patients treated in the National Cancer Center Hospital in Japan. 25 Prior to this publication, Japanese surgeons had demonstrated a high incidence of nodal metastasis in the different stations but had never shown the efficacy of surgery by survival rate. After this paper was published, these figures were called "dissection efficacy index" and started to be widely used in other cancer types to evaluate the efficacy of nodal dissection by station.
| Introduction of the insulation-tipped diathermic knife (IT knife) and endoscopic submucosal dissection (ESD)
In the 1990s, Dr Hosokawa invented the IT knife for ESD, which is now widely used to treat EGC as well as some early colon cancers. 26 As the technique of ESD continues to improve, there are increasing indications for the use of ESD.
| Back to the uncertainty about adjuvant chemotherapy
At the beginning of the 1990s, the majority of Japanese surgeons believed in the efficacy of adjuvant chemotherapy for curatively resected advanced gastric cancer, despite the lack of quality evidence. poor patient accrual. 27 The final results of this study published some years later, unexpectedly, showed the significant effect of adjuvant chemotherapy in spite of the small number of enrolled patients. The discussion during this decade changed the mind of surgeons in Japan from accepting surgery followed by adjuvant chemotherapy as the standard of care to accepting surgery alone as the standard treatment for gastric cancer.
| Additional effective drugs for gastric cancer
In the 1990s, a global phase III study was carried out to evaluate the efficacy and safety of the combination of 5FU, leucovorin, adriamycin,
methotrexate (FAMTX) vs etoposide, adriamycin and cisplatin (EAP).
This trial showed an improved response rate and median survival time with less toxicity for FAMTX. 28 As this regimen turned out, however, intolerable for majority of Japanese patients, the Japan Gastric Cancer Association (JGCA) guideline of 2001 29 did not recommend it.
| ER A OF E VIDEN CE
| Gastric cancer treatment guidelines by JGCA
In 2001, the first gastric cancer treatment guideline was published by JGCA. 29 Before this guideline came out, the level of lymphadenectomy, type of reconstruction, and the chemotherapeutic regimen for both the adjuvant and metastatic setting was quite variable across the country. Since the release of the first set of Guidelines in 2001, regular revisions have been made and the idea of a "gold standard" in gastric cancer treatment has been gradually established.
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| Clinical trials on gastric cancer surgery
After 2000, many important clinical studies have been carried out in the field of gastric cancer surgery. JCOG0110, the first noninferiority trial conducted by the JCOG Gastric Cancer Surgery Group, evaluated spleen preserving total gastrectomy (D2 without splenic hilum nodes and nodes along the distal splenic artery) vs standard D2 total gastrectomy with splenectomy. In this study, the non-inferiority of spleen preserving total gastrectomy was established in cases where the tumor does not involve the greater curvature. 32 Published trials on gastric cancer surgery by JCOG are summarized in Table 2 .
| Minimally invasive surgery
Since 2000, laparoscopic gastrectomy (LG), especially distal gastrectomy (LDG) has been increasingly used for gastric cancer surgery.
There is currently sufficient evidence to support the non-inferiority 
| Function preserving surgery for EGC
Pylorus preserving gastrectomy (PPG) was initially reported in the 1980s for peptic ulcer treatment. This operation gained popularity in Japan in the 2000s for EGC, 38, 39 but the number of surgeons who continue to perform this surgery has decreased because of the wide application of LG for gastric cancer. Theoretically, laparoscopic PPG is feasible but is much more complicated than standard LDG. As the majority of patients get accustomed to surgical sequela, such as dumping syndrome, 38 within a few years, surgeons currently don't adequately weigh the patient benefit of retaining pyloric function against the convenience of the surgeons, to the author's great regret.
The JGCA treatment guidelines propose proximal gastrectomy for small EGC arising near the cardia. 31 Several methods of reconstruction have been reported for this procedure. The pros and cons of the various techniques are summarized in Table 3 . As shown in in QOL of other types of LG. The figure of gastroscopy of the remnant stomach is an eloquent demonstration of the potential benefit of Kamikawa's operation ( Figure 1A ,B).
| Development of adjuvant therapy
Since S-1, a combination drug of tegafur, gimeracil, and oteracil had 
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The success in conducting this trial was owing to wide acceptance of the uncertainty of benefit from adjuvant treatment in Japan, allowing the use of the surgery-alone control arm, which was impossible in the 1980s.
In 2009, a Korean RCT, the CLASSIC study, also showed significant benefit of adjuvant chemotherapy using xeloda plus oxaliplatin (XELOX) for stage II/III gastric cancer. 42 Recently, after the Japanese Government approved the use of oxaliplatin for gastric cancer, this combination and another combination of S-1 plus oxaliplatin (SOX)
were tested for feasibility as adjuvant treatment in Japanese patients.
Both treatments were proven to be tolerable by Japanese patients and the post hoc survival analysis showed good survival results, although Abbreviations: EGJ, esophago-gastric junctional adenocarcinoma; LADG, laparoscopy assisted distal gastrectomy; LPG, laparoscopic proximal gastrectomy; LTG, laparoscopic total gastrectomy; PAND, para-aortic lymph node dissection. (Tables 4 and 5) . 48 
TA B L E 2
Clinical studies on surgical treatment of gastric cancer by JCOG
| Evidence for wider application of ESD
The JCOG Endoscopic Treatment Group has performed several prospective confirmatory studies for large-size mucosal cancers of differentiated histology (JCOG0607) and for small (≤2 cm)
poorly undifferentiated type including signet ring cell tumors (JCOG1009/1010). Both trials showed adequate overall and relapsefree survival 49, 50 such that ESD is noe the first-choice treatment for patients with these lesions. treatment in combination with paclitaxel. Immune checkpoint inhibitors are expected to be used more and more, awaiting the results of the studies on efficacy as adjuvant or neo-adjuvant treatment.
| New drugs have become available in this era
| SUMMARY
In the last 50 years, treatment of gastric cancer has changed dramatically due to the acceptance of scientific evidence from trials and the development of new chemotherapy drugs. Given the rapid and remarkable aging of the Japanese population, the importance of non-surgical treatments will continue to increase. It seems possible that ESD combined with "gentler" chemotherapy or immunotherapy may enable stomach preserving treatment in more than half of gastric cancer patients. On the other hand, if the phenomenon of increased incidence of signet ring cell cancer among young adults occurs, as in the USA, aggressive multimodal treatment will continue to be necessary, including D2 gastrectomy.
The 3-year RFS of the S-1 arm in the JACCRO GC-07 trial was 10%
worse than that of stage III patients of the ACTS-GC and almost as bad as that of the S-1 monotherapy arm in the JCOG0501 study, which included 40% or more stage IV patients. We must be vigilant about maintaining high standards for gastric cancer surgery as this remains the single most important aspect of treatment. It is too early to make light of good local control by D2 surgery since the chemotherapy for this cancer is much less effective than that for breast cancer.
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